Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.
CT.gov Identifier
EudraCT Identifier
N/A
CTIS:
N/A
Sponsor
Boehringer Ingelheim
Collaborator
Yale University
Study Contact Information
Recruiting
Study Details
Diseases
Chronic Kidney Disease
Study Drug
Empagliflozin
Genes
N/A
Study Dates
Mar 2023 - Dec 2025
Sex
Female & Male
Age
18+ years
Inclusion and Exclusion Criteria
Inclusion Criteria:
- Patients actively undergoing PD with a reliably functioning PD catheter
- Stable peritoneal dialysis prescription
- PD vintage > 3 months
- Age >18 years of age
Exclusion Criteria:
- History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months
- Use of an SGLT2 inhibitor within the prior 30 days
- 1 or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter
- Anemia with hemoglobin <8g/dL
- Inability to give written informed consent or follow study protocol
- Contraindication to receiving loop diuretics
Protocol Summary
The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis.
Study Locations
To view all trial locations, click here
Contact Us About More Information for the Clinical Trial Concierge Service
Natera’s Clinical Trial Concierge Program is comprised of a dedicated team that helps connect providers and patients with appropriate clinical trials. To learn more about a trial offered through this service, please complete the form below.
Fields marked with asterisk (*) are mandatory.